TEL: 044-952-0102


Focal Segmental Glomerulosclerosis (FSGS) Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 704960
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
本日の銀行送金レート: 1USD=111.91円で換算しております。
Back to Top
世界の巣状糸球体硬化症(FSGS)治療市場:疾患タイプ、疾患管理、地域別 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 120 Pages




第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 成長要因
    • 疾病負荷の上昇
    • 新たな治療法の開発に向けた研究開発活動
    • 稀少疾患への公的資金の投入
  • 阻害要因
    • 腎臓移植および透析のコストの高さ
    • 病態についての理解の低さ
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 疾患タイプ別
    • 一次性(突発性)
    • 二次性(続発性)
  • 疾患管理別
    • 診断
    • 治療
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • B. Braun Melsungen AG
  • Beckman Coulter Inc. (Danaher)
  • Boston Scientific Corporation
  • ChemoCentryx Inc.
  • Complexa Inc
  • Dimerix
  • Medtronic
  • Pfizer Inc.
  • Retrophin Inc.
  • Variant Pharmaceuticals Inc

第10章 市場の将来展望

Product Code: 64100

In comparison to other glomerular diseases, the prevalence of FSGS is growing fast worldwide. It is becoming as one of the primary contributors to end-stage renal disease (ESRD), as reported in a 2017 publication, in Clinical Journal of American Society of Nephrology. It accounts for approximately 20% of cases of the nephrotic syndrome in children and about 40% of cases in adults, with nearly seven being diagnosed in 1 million population. Males have 1.5 to 2 folds higher risk of developing this disease over the whole life period.

As per the NephCure, each year, about more than 5,400 patients are diagnosed with FSGS and about 20,000 patients with ESRD were earlier affected due to FSGS. In addition, people of African ancestry have five times higher diagnosis rate, and those who do not respond to the steroids move for kidney transplant or dialysis, wherein 30%-40% of patients, the FSGS disease recurs. Further, as per the University of California, the ESRD is increasing by 5% each year. With that, the need for donor's kidneys is rising by 8% each year.

Both developed and emerging markets are going through increasing demand for the kidney transplants and a higher rate of hospitalizations, due to kidney malfunction. This increases the demand to diagnose the initial stage of FSGS diseases during the treatment of kidney diseases. The recurrence of FSGS is quite frequent after the kidney transplant, and nearly half of the patients with recurrent FSGS lose their transplanted kidney within five years, as per the UNC Kidney Center, 2018. Thus, the burden of glomerulus-related disorders drives the demand for the FSGS market over the forecast period.

Key Market Trends

Primary FSGS is Expected to Register Highest CAGR in the Disease Type Segment

The primary FSGS is usually "idiopathic," referring to rise of disease without any known, definite or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. The current therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Steroid therapy is among the most basic and standard treatment with oral prednisone.

As per a 2016 publication in Biomed Research International, about 80% of cases of FSGS primary or idiopathic. Furthermore, a significant number of FSGS cases are resistant to steroid treatment, which is leading to high demand for better-targeted therapies. Some of the major emerging companies having their potential drug candidates in the pipeline are Chemocentryx, Reata, Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals.

Since it is a rare disease, specialty clinical-stage companies are likely to get more funds and are leveraging the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments. Hence, owing to the above-mentioned statements, it has been observed that the segment will have rapid growth over the forecast period.

United States to Have the Largest Share of the Market in the North America Region

The increasing prevalence of FSGS, the presence of state-of-the-art healthcare infrastructure, the high adoption rate of new healthcare technology, and presence of reimbursements are facilitating the market growth. As per the NephroCure Kidney International, about 8,000 individuals are newly diagnosed each year with FSGS and nephrotic syndrome.

It is the leading cause of kidney failure among children, and in the African-American community, this disease is five times more common. Moreover, the country is among the first choice for several manufacturers to conduct clinical trials. Majority of FSGS clinical trials have happened or are in progress in the United States, with high involvement of universities and research centers involved in the funding of the trials, dominated by drugs under trials. For FSGS, several clinical trials and approvals for clinical trials of drugs are under process, which makes this market a highly lucrative over the forecast period.

Competitive Landscape

The market for FSGS Treatment is moderately consolidated and consists of the global players that are into the medical devices business that provide products related to dialysis or other diagnostics. The major pharmaceutical companies involved in this market are having their products in the pipeline and are expected to release their products in the coming years.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Focal Segmental Glomerulosclerosis (FSGS)
    • 4.2.2 High Focus on Developing New Treatment Options
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Dialysis and Kidney Transplant
    • 4.3.2 Insufficient Understanding of the Disease Pathophysiology
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Disease Type
    • 5.1.1 Primary FSGS
    • 5.1.2 Secondary FSGS
  • 5.2 By Disease Management
    • 5.2.1 Diagnosis
      • Kidney Biopsy
      • Creatinine Test
      • Other Diagnoses
    • 5.2.2 Treatment
      • Drug Therapy
      • Dialysis
      • Kidney Transplant
  • 5.3 Geography
    • 5.3.1 North America
      • US
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 B. Braun Melsungen AG
    • 6.1.2 Beckman Coulter Inc. (Danaher)
    • 6.1.3 Baxter International Inc.
    • 6.1.4 ChemoCentryx Inc.
    • 6.1.5 Complexa Inc.
    • 6.1.6 Dimerix Ltd
    • 6.1.7 Medtronic PLC
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Retrophin Inc.
    • 6.1.10 Variant Pharmaceuticals Inc.


Back to Top